Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02953379
Recruitment Status : Withdrawn (Sponsor decision)
First Posted : November 2, 2016
Last Update Posted : November 4, 2020
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: EMS Mometasone gel Drug: Mometasone spray nasal Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Adults
Estimated Study Start Date : May 2019
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: EMS Mometasone gel
The patient should administer 2 spray in each nostril, once daily.
Drug: EMS Mometasone gel
The patient should administer 2 spray in each nostril, once daily.

Active Comparator: Mometasone spray nasal
The patient should administer 2 spray in each nostril, once daily.
Drug: Mometasone spray nasal
The patient should administer 2 spray in each nostril, once daily.
Other Name: Nasonex

Primary Outcome Measures :
  1. Efficacy of allergic rhinitis treatment based proportion of participants who show at least moderate relief [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Safety will be evaluated by the adverse events occurrences [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed Consent of the patient;
  • Clinical diagnosis of moderate - severe persistent allergic rhinitis according to ARIA classification(Allergic Rhinitis and Its Impact on Asthma);

Exclusion Criteria:

  • Patients with any clinically significant disease that in the investigator is opinion can

    ´t participate in the study;

  • Patients with any laboratory finding or image finding that in the investigator is opinion can´t participate in the clinical trial;
  • Patients with history of hypersensitivity to any of the formula compounds;
  • Participation in clinical trial in the year prior to this study;
  • Pregnancy or risk of pregnancy and lactating patients;
  • Patients who were in use of drugs that can interfere with evaluation;
  • Decongestants dependent patients or patients receiving allergen specific immunotherapy;
  • Patients on treatment with monoamine oxidase inhibitors (MAOIs);
  • History of hypertension, coronary artery disease, cardiac arrhythmias, glaucoma, hyperthyroidism and / or prostatic hypertrophy.
Layout table for additonal information
Responsible Party: EMS Identifier: NCT02953379    
Other Study ID Numbers: EMS1315
First Posted: November 2, 2016    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Respiratory Tract Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Mometasone Furoate
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents